2j4e: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
 
(23 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Image:2j4e.gif|left|200px]]<br />
<applet load="2j4e" size="450" color="white" frame="true" align="right" spinBox="true"
caption="2j4e, resolution 2.80&Aring;" />
'''THE ITP COMPLEX OF HUMAN INOSINE TRIPHOSPHATASE'''<br />


==Overview==
==THE ITP COMPLEX OF HUMAN INOSINE TRIPHOSPHATASE==
Inosine triphosphatase (ITPA) is a ubiquitous key regulator of cellular, non-canonical nucleotide levels. It breaks down inosine and xanthine, nucleotides generated by deamination of purine bases. Its enzymatic action, prevents accumulation of ITP and reduces the risk of incorporation of, potentially mutagenic inosine nucleotides into nucleic acids. Here we, describe the crystal structure of human ITPA in complex with its prime, substrate ITP, as well as the apoenzyme at 2.8 and 1.1A, respectively., These structures show for the first time the site of substrate and Mg2+, coordination as well as the conformational changes accompanying substrate, binding in this class of enzymes. Enzyme substrate interactions induce an, extensive closure of the nucleotide binding grove, resulting in tight, ... [[http://ispc.weizmann.ac.il/pmbin/getpm?17138556 (full description)]]
<StructureSection load='2j4e' size='340' side='right'caption='[[2j4e]], [[Resolution|resolution]] 2.80&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[2j4e]] is a 8 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2J4E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2J4E FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.8&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=IMP:INOSINIC+ACID'>IMP</scene>, <scene name='pdbligand=ITT:INOSINE+5-TRIPHOSPHATE'>ITT</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=POP:PYROPHOSPHATE+2-'>POP</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2j4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2j4e OCA], [https://pdbe.org/2j4e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2j4e RCSB], [https://www.ebi.ac.uk/pdbsum/2j4e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2j4e ProSAT]</span></td></tr>
</table>
== Disease ==
[https://www.uniprot.org/uniprot/ITPA_HUMAN ITPA_HUMAN] Defects in ITPA are the cause of inosine triphosphate pyrophosphohydrolase deficiency (ITPAD) [MIM:[https://omim.org/entry/613850 613850]. It is a common inherited trait characterized by the abnormal accumulation of inosine triphosphate (ITP) in erythrocytes and also leukocytes and fibroblasts. The pathological consequences of ITPA deficiency, if any, are unknown. However, it might have pharmacogenomic implications and be related to increased drug toxicity of purine analog drugs. Note=Three different human populations have been reported with respect to their ITPase activity: high, mean (25% of high) and low activity. The variant Thr-32 is associated with complete loss of enzyme activity, may be by altering the local secondary structure of the protein. Heterozygotes for this polymorphism have 22.5% of the control activity: this is consistent with a dimeric structure of the enzyme.[:]<ref>PMID:12384777</ref> <ref>PMID:12436200</ref>
== Function ==
[https://www.uniprot.org/uniprot/ITPA_HUMAN ITPA_HUMAN] Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective monophosphate derivatives. The enzyme does not distinguish between the deoxy- and ribose forms. Probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal lesions.<ref>PMID:17090528</ref>
== Evolutionary Conservation ==
[[Image:Consurf_key_small.gif|200px|right]]
Check<jmol>
  <jmolCheckbox>
    <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/j4/2j4e_consurf.spt"</scriptWhenChecked>
    <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
    <text>to colour the structure by Evolutionary Conservation</text>
  </jmolCheckbox>
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=2j4e ConSurf].
<div style="clear:both"></div>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Inosine triphosphatase (ITPA) is a ubiquitous key regulator of cellular non-canonical nucleotide levels. It breaks down inosine and xanthine nucleotides generated by deamination of purine bases. Its enzymatic action prevents accumulation of ITP and reduces the risk of incorporation of potentially mutagenic inosine nucleotides into nucleic acids. Here we describe the crystal structure of human ITPA in complex with its prime substrate ITP, as well as the apoenzyme at 2.8 and 1.1A, respectively. These structures show for the first time the site of substrate and Mg2+ coordination as well as the conformational changes accompanying substrate binding in this class of enzymes. Enzyme substrate interactions induce an extensive closure of the nucleotide binding grove, resulting in tight interactions with the base that explain the high substrate specificity of ITPA for inosine and xanthine over the canonical nucleotides. One of the dimer contact sites is made up by a loop that is involved in coordinating the metal ion in the active site. We predict that the ITPA deficiency mutation P32T leads to a shift of this loop that results in a disturbed affinity for nucleotides and/or a reduced catalytic activity in both monomers of the physiological dimer.


==About this Structure==
Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T.,Stenmark P, Kursula P, Flodin S, Graslund S, Landry R, Nordlund P, Schuler H J Biol Chem. 2007 Feb 2;282(5):3182-7. Epub 2006 Nov 29. PMID:17138556<ref>PMID:17138556</ref>
2J4E is a [[http://en.wikipedia.org/wiki/Single_protein Single protein]] structure of sequence from [[http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]] with MG, ITT, POP and IMP as [[http://en.wikipedia.org/wiki/ligands ligands]]. Active as [[http://en.wikipedia.org/wiki/Nucleoside-triphosphate_diphosphatase Nucleoside-triphosphate diphosphatase]], with EC number [[http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.6.1.19 3.6.1.19]]. Structure known Active Site: AC1. Full crystallographic information is available from [[http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2J4E OCA]].


==Reference==
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T., Stenmark P, Kursula P, Flodin S, Graslund S, Landry R, Nordlund P, Schuler H, J Biol Chem. 2007 Feb 2;282(5):3182-7. Epub 2006 Nov 29. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17138556 17138556]
</div>
<div class="pdbe-citations 2j4e" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Nucleoside-triphosphate diphosphatase]]
[[Category: Large Structures]]
[[Category: Single protein]]
[[Category: Arrowsmith C]]
[[Category: Arrowsmith, C.]]
[[Category: Berglund H]]
[[Category: Berg, S.Van.Den.]]
[[Category: Busam R]]
[[Category: Berglund, H.]]
[[Category: Collins R]]
[[Category: Busam, R.]]
[[Category: Edwards A]]
[[Category: Collins, R.]]
[[Category: Ehn M]]
[[Category: Edwards, A.]]
[[Category: Flodin S]]
[[Category: Ehn, M.]]
[[Category: Flores A]]
[[Category: Flodin, S.]]
[[Category: Graslund S]]
[[Category: Flores, A.]]
[[Category: Hallberg BM]]
[[Category: Graslund, S.]]
[[Category: Hammarstrom M]]
[[Category: Hallberg, B.M.]]
[[Category: Hogbom M]]
[[Category: Hammarstrom, M.]]
[[Category: Holmbergschiavone L]]
[[Category: Hogbom, M.]]
[[Category: Kotenyova T]]
[[Category: Kotenyova, T.]]
[[Category: Kursula P]]
[[Category: Kursula, P.]]
[[Category: Landry R]]
[[Category: Landry, R.]]
[[Category: Loppnau P]]
[[Category: Loppnau, P.]]
[[Category: Magnusdottir A]]
[[Category: Magnusdottir, A.]]
[[Category: Nilsson-Ehle P]]
[[Category: Nilsson-Ehle, P.]]
[[Category: Nordlund P]]
[[Category: Nordlund, P.]]
[[Category: Nyman T]]
[[Category: Nyman, T.]]
[[Category: Ogg D]]
[[Category: Ogg, D.]]
[[Category: Persson C]]
[[Category: Persson, C.]]
[[Category: Sagemark J]]
[[Category: Sagemark, J.]]
[[Category: Schuler H]]
[[Category: Schiavone, L.Holmberg.]]
[[Category: Stenmark P]]
[[Category: Schuler, H.]]
[[Category: Sundstrom M]]
[[Category: Stenmark, P.]]
[[Category: Thorsell AG]]
[[Category: Sundstrom, M.]]
[[Category: Uppenberg J]]
[[Category: Thorsell, A.G.]]
[[Category: Van Den Berg S]]
[[Category: Uppenberg, J.]]
[[Category: Wallden K]]
[[Category: Wallden, K.]]
[[Category: Weigelt J]]
[[Category: Weigelt, J.]]
[[Category: IMP]]
[[Category: ITT]]
[[Category: MG]]
[[Category: POP]]
[[Category: disease mutation]]
[[Category: hydrolase]]
[[Category: imp]]
[[Category: inosine triphosphatase deficiency]]
[[Category: inosine triphosphate pyrophosphohydrolase]]
[[Category: itp]]
[[Category: nucleotide metabolism]]
 
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Oct 30 17:23:54 2007''

Latest revision as of 17:33, 13 December 2023

THE ITP COMPLEX OF HUMAN INOSINE TRIPHOSPHATASETHE ITP COMPLEX OF HUMAN INOSINE TRIPHOSPHATASE

Structural highlights

2j4e is a 8 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 2.8Å
Ligands:, , ,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Disease

ITPA_HUMAN Defects in ITPA are the cause of inosine triphosphate pyrophosphohydrolase deficiency (ITPAD) [MIM:613850. It is a common inherited trait characterized by the abnormal accumulation of inosine triphosphate (ITP) in erythrocytes and also leukocytes and fibroblasts. The pathological consequences of ITPA deficiency, if any, are unknown. However, it might have pharmacogenomic implications and be related to increased drug toxicity of purine analog drugs. Note=Three different human populations have been reported with respect to their ITPase activity: high, mean (25% of high) and low activity. The variant Thr-32 is associated with complete loss of enzyme activity, may be by altering the local secondary structure of the protein. Heterozygotes for this polymorphism have 22.5% of the control activity: this is consistent with a dimeric structure of the enzyme.[:][1] [2]

Function

ITPA_HUMAN Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective monophosphate derivatives. The enzyme does not distinguish between the deoxy- and ribose forms. Probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal lesions.[3]

Evolutionary Conservation

Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

Publication Abstract from PubMed

Inosine triphosphatase (ITPA) is a ubiquitous key regulator of cellular non-canonical nucleotide levels. It breaks down inosine and xanthine nucleotides generated by deamination of purine bases. Its enzymatic action prevents accumulation of ITP and reduces the risk of incorporation of potentially mutagenic inosine nucleotides into nucleic acids. Here we describe the crystal structure of human ITPA in complex with its prime substrate ITP, as well as the apoenzyme at 2.8 and 1.1A, respectively. These structures show for the first time the site of substrate and Mg2+ coordination as well as the conformational changes accompanying substrate binding in this class of enzymes. Enzyme substrate interactions induce an extensive closure of the nucleotide binding grove, resulting in tight interactions with the base that explain the high substrate specificity of ITPA for inosine and xanthine over the canonical nucleotides. One of the dimer contact sites is made up by a loop that is involved in coordinating the metal ion in the active site. We predict that the ITPA deficiency mutation P32T leads to a shift of this loop that results in a disturbed affinity for nucleotides and/or a reduced catalytic activity in both monomers of the physiological dimer.

Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T.,Stenmark P, Kursula P, Flodin S, Graslund S, Landry R, Nordlund P, Schuler H J Biol Chem. 2007 Feb 2;282(5):3182-7. Epub 2006 Nov 29. PMID:17138556[4]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

  1. Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, Thein SL, Ansari A, Sanderson J, De Abreu RA, Simmonds HA, Duley JA. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002 Oct;111(4-5):360-7. Epub 2002 Aug 15. PMID:12384777 doi:10.1007/s00439-002-0798-z
  2. Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet. 2002;47(11):620-2. PMID:12436200 doi:10.1007/s100380200095
  3. Burgis NE, Cunningham RP. Substrate specificity of RdgB protein, a deoxyribonucleoside triphosphate pyrophosphohydrolase. J Biol Chem. 2007 Feb 9;282(6):3531-8. Epub 2006 Nov 6. PMID:17090528 doi:M608708200
  4. Stenmark P, Kursula P, Flodin S, Graslund S, Landry R, Nordlund P, Schuler H. Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T. J Biol Chem. 2007 Feb 2;282(5):3182-7. Epub 2006 Nov 29. PMID:17138556 doi:10.1074/jbc.M609838200

2j4e, resolution 2.80Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA